Factors such as the increasing R&D activities and expenditure in the life science industry, increasing funding for proteomics research and drug discovery, and the growing collaboration between industries and academic institutes are the key drivers of the research antibodies market.
The Research Antibodies Market is expected to reach USD 12.60 Billion by 2022 from an estimated USD 9.33 Billion in 2017, at a CAGR of 6.2% during the forecast period.
Download PDF Brochure: – https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=94212793
Based on technology, the western blotting segment accounted for the largest share of the research antibodies market. Its ability to quantify as little as 0.1 nanograms of protein in a sample with high specificity makes it an indispensable tool in proteomic research; this is the key factor driving market growth.
On the basis of product, the reagents segment accounted for the largest share of the global research antibodies market (including reagents), in 2016. This can be attributed to the fact that a large number of reagents are used in various routine assays and techniques.
Based on application, the proteomics segment accounted for the largest share of the research antibodies market. The large share of this segment is attributed to the deployment of proteomic-based approaches in biomarker detection and cancer profiling, increasing R&D expenditure, and availability of funds from various organizations.
Based on end user, the pharmaceutical & biotechnological companies segment accounted for the largest share of the research antibodies market owing to the high uptake of research-specific antibodies in the drug discovery and development process, along with the increasing use of these research tools in the ever-developing proteomics research sector.
North America accounted for the largest share of the research antibodies market in 2016, followed by Europe.
Speak To Analyst: – https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=94212793
The major players in the research antibodies market (including reagents) are Thermo Fisher Scientific, Inc. (U.S.), Merck Group , Abcam plc (U.K.), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), GenScript (U.S.), PerkinElmer, Inc. (U.S.), Lonza (Switzerland), and BioLegend, Inc. (U.S.).
